14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.90 $17.25 Wednesday, 1st May 2024 VRNA stock ended at $15.22. This is 1.49% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 3.49% from a day low at $15.20 to a day high of $15.73.
90 days $14.90 $19.10
52 weeks $11.83 $23.81

Historical Verona Pharma plc prices

Date Open High Low Close Volume
May 18, 2017 $13.50 $13.60 $13.50 $13.52 4 128
May 17, 2017 $13.33 $13.45 $13.33 $13.45 603
May 16, 2017 $13.49 $13.52 $13.49 $13.51 2 479
May 15, 2017 $13.57 $13.57 $13.50 $13.51 6 334
May 12, 2017 $13.50 $13.73 $13.50 $13.50 2 404
May 11, 2017 $13.52 $13.52 $13.50 $13.52 2 714
May 10, 2017 $13.51 $13.73 $13.50 $13.52 8 352
May 09, 2017 $13.60 $13.60 $13.50 $13.52 1 956
May 08, 2017 $13.50 $13.60 $13.50 $13.50 4 054
May 05, 2017 $13.50 $13.55 $13.50 $13.50 6 762
May 04, 2017 $13.63 $13.63 $13.50 $13.52 7 428
May 03, 2017 $13.50 $13.58 $13.50 $13.51 3 882
May 02, 2017 $13.52 $13.53 $13.50 $13.50 11 901
May 01, 2017 $13.60 $13.85 $11.05 $13.52 26 843
Apr 28, 2017 $13.50 $13.56 $13.50 $13.50 37 531
Apr 27, 2017 $13.50 $13.89 $13.50 $13.50 586 652
Click to get the best stock tips daily for free!

About Verona Pharma plc

Verona Pharma plc Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ... VRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT